Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703464 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL2694822 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL1679669 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL1704321 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL10312301 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL5696662 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL11326328 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL11335730 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| SCHEMBL5020900 | 0.97 | PPARA (0.64) | PPARACA2CA1CA12CA7 | |
| Bromide SCHEMBL5709142 | 0.95 | PPARA (0.61) | PPARACA2CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649091-B1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | STICHTING NL KANKER INST (NL) | 2014-10-01 | — | — | EP | claimed |
| US-20140004137-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | STICHTING SANQUIN BLOEDVOORZIENING (NL) | 2014-01-02 | — | — | US | claimed |
| EP-2649091-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | Stichting Het Nederlands Kanker Instituut (NL) | 2013-10-16 | — | — | EP | claimed |
| WO-2012076708-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | STICHTING HET NEDERLANDS KANKER INSTITUUT (NL) | 2012-06-14 | — | — | WO | claimed |
| EP-0705251-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-04-10 | — | — | EP | claimed |
| WO-1995000493-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | claimed |
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MordernaTX, Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190314292-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2019-10-17 | — | — | US | disclosed |
| US-9289516-B2 | Imaging beta cell mass | THE GENERAL HOSPITAL CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| WO-2015089152-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8865705-B2 | Benzimidazole respiratory syncytial virus inhibitors | JANSSEN R&D IRELAND (IE) | 2014-10-21 | — | — | US | disclosed |
| EP-2649091-B1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | STICHTING NL KANKER INST (NL) | 2014-10-01 | — | — | EP | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| US-6326500-B1 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | ABBOTT LABORATORIES | 2001-12-04 | — | — | US | disclosed |
| US-6215001-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS, AND ANTIALLERGENS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-04-10 | — | — | US | disclosed |
| WO-2001004100-A1 | PROCESS FOR PREPARING 2-AMINO-4-(4-FLUORPHENYL)-6-ALKYLPYRIMIDINE-5-CARBOXYLATE | LONZA AG (CH) | 2001-01-18 | — | — | WO | disclosed |
| US-6031109-A | Phenoxy-, phenylthio-, benzoyl-alkyleneaminoalkylene-imidazole derivatives as therapeutic agents | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5780642-A | NON-STEROIDAL ANTIINFLAMMATORY AGENT WHICH BLOCKS RELEASE OF ARACHIDONIC ACID FROM PHOSPHOLIPIDS; SIDE EFFECT REDUCTION | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| WO-1995000493-A1 | IMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140004137-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | TAP2, HLA-DRB1, HLA-C | PPARA 900/4885CA2 1327/4885CA1 822/4885 |
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | PPARA 1416/4885CA2 4394/4885CA1 4349/4885 |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | PPARA 3031/4885CA2 1789/4885CA1 2339/4885 |
| US-20190314292-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | PPARA 1416/4885CA2 4394/4885CA1 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.